Breathe Well Live Well-SM
EurekAlert (press release) |
Novel gene therapy shows potential for lung repair in asthma American Thoracic Society
EurekAlert (press release) ATS 2016, SAN FRANCISCO — A new study has demonstrated a way to deliver a nanoparticle-based gene therapy, in order to repair lungs damaged by chronic allergic asthma and to reduce inflammation that causes asthma attacks. The potential therapy … |
View full post on asthma – Google News
|
Asthma is associated with polycystic ovary syndrome and excess weight The Endocrine Society
EurekAlert (press release) Boston, MA–Among reproductive-age women, polycystic ovary syndrome (PCOS) as well as overweight and obesity are independently linked with asthma, new preliminary research from Australia suggests. The results will be presented in a poster Saturday, … |
View full post on asthma – Google News
|
Vitamin D does not reduce colds in asthma patients American Thoracic Society
EurekAlert (press release) 23, 2015 – Vitamin D supplements do not reduce the number or severity of colds in asthma patients, according to a new study published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care … Vitamin D does not reduce cold severity, frequency in adults with asthma |
View full post on asthma – Google News
|
Asthma Society Receives Gift of over $200000 to Support Asthma Research
RushPRnews.com (press release) TORONTO, ON (RPRN) 10/15/15 — The Asthma Society of Canada (ASC) is pleased to announce the creation of the Dr. Goran Enhorning Asthma Research Fund after receiving an unprecedented gift of $230,000 from the Dr. Goran Enhorning Foundation for … |
View full post on asthma – Google News
 |
Related Articles |
Asthma and COPD: Interchangeable use of inhalers. A document of Italian Society of Allergy, Asthma and Clinical Immmunology (SIAAIC) & Italian Society of Respiratory Medicine (SIMeR).
Pulm Pharmacol Ther. 2015 Jul 22;
Authors: Lavorini F, Braido F, Baiardini I, Blasi F, Canonica GW, SIAAC-SIMER
Abstract
Prescription cost-containment measures are increasing in many European countries and, as more inhaler devices become available, there may be pressure to switch patients from reference listed inhaler medication to cheaper generic inhaler drugs. Indeed, in some countries, such a substitution is mandated by current regulations, and patients who do not accept the substitution have to pay the difference in cost. Generic inhaled drugs are therapeutically equivalent to original branded options but may differ in their formulation and inhalation device. This new situation raises questions about the potential impact of switching from branded to generic inhaled medications in patients with asthma or chronic obstructive pulmonary disease (COPD), with or without their consent, in countries where this is permitted. Acquisition cost savings from a substitution could be offset by costs related to deterioration in asthma control or worsening in COPD outcomes if the patient is unable or unwilling to use the inhaler device properly. Non-adherence to therapy and incorrect inhaler usage are recognised as major factors in uncontrolled asthma and worsening of COPD outcomes. Switching patients to a different inhaler device may exacerbate these problems, particularly in patients who disagree to switch. Where switching is permitted or mandatory, it is crucial that the reason for switching has been properly explained to the patient and adequate instruction for operating correctly the inhaler have clearly been provided.
PMID: 26209820 [PubMed – as supplied by publisher]
View full post on pubmed: asthma